Calcium channel blockers and the incidence of breast and prostate cancer: A meta-analysis

Autor:	R. A. Forse, M. M. Garcia-Betancourt, X. Wang, A. A. Thakur
Rok vydání:	2018
Předmět:	Adult Male Risk 0301 basic medicine Oncology medicine.medical_specialty Adolescent Breast Neoplasms Young Adult 03 medical and health sciences Prostate cancer 0302 clinical medicine Breast cancer Internal medicine Odds Ratio Humans Medicine Pharmacology (medical) Aged Cause of death Pharmacology business.industry Incidence Incidence (epidemiology) Prostatic Neoplasms Cancer Publication bias Odds ratio Middle Aged Calcium Channel Blockers medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Meta-analysis Female business
Zdroj:	Journal of Clinical Pharmacy and Therapeutics. 43:519-529
ISSN:	0269-4727
DOI:	10.1111/jcpt.12673
Popis:	What is known and objective Breast cancer (BCa) and prostate cancer (PCa), both hormone-dependent cancers, are the second leading cause of death in both women and men, respectively. Calcium channel blockers (CCBs) have been thought to increase the risk of cancer by inhibiting calcium signal-mediated apoptosis, but the evidence for this association remains inconclusive. We have reviewed pertinent literature and pooled data to establish a consensus on the relationship of CCB use and the incidence of these two cancers. Methods PubMed was used to conduct a search for English articles from inception to April 2016. Relevant data including study design, number of total participants and CCB users, total cases of BCa and PCa, age (mean and/or range), follow-up period and statistical outcomes were retrieved. Quality assessment was carried out using Newcastle Ottawa system, with the selection of high-quality studies. Summary effects were obtained using random- and mixed-effects models, followed by sensitivity analysis, and testing for publication bias. Results and discussion This meta-analysis includes 11 relevant studies for BCa and 6 for PCa. The odds ratio (OR) association between BCa and CCB use was 1.14 (95%CI: 1.02, 1.27, P = .02). The OR association between PCa and CCB use was 1.12 (95%CI .94-1.35, P = .21). What is new and conclusion Although a statistically significant association between CCB use and incidence of BCa does exist, the limitations of the individual studies restrict the clinical application of this relationship. Our meta-regression model does newly identify a 9-year latency period of CCB use and a significantly increased risk of BCa. No significant association exists between CCB use and the incidence of PCa. Our meta-regression shows CCB may have a protective effect upon PCa incidence among older populations.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32aec676b14db6083a4700f40d2ce81 https://doi.org/10.1111/jcpt.12673 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.